Presbia PLC (NASDAQ: LENS) and Hologic (NASDAQ:HOLX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Analyst Ratings

This is a summary of recent ratings for Presbia PLC and Hologic, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Presbia PLC 0 0 3 0 3.00
Hologic 0 4 9 0 2.69

Presbia PLC currently has a consensus target price of $11.33, suggesting a potential upside of 145.84%. Hologic has a consensus target price of $47.77, suggesting a potential upside of 31.67%. Given Presbia PLC’s stronger consensus rating and higher possible upside, analysts plainly believe Presbia PLC is more favorable than Hologic.

Insider and Institutional Ownership

16.5% of Presbia PLC shares are owned by institutional investors. Comparatively, 96.4% of Hologic shares are owned by institutional investors. 74.7% of Presbia PLC shares are owned by company insiders. Comparatively, 0.8% of Hologic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Presbia PLC and Hologic’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Presbia PLC $13,000.00 6,012.86 -$16.76 million ($1.20) -3.84
Hologic $2.98 billion 3.41 $1.01 billion $2.68 13.54

Hologic has higher revenue and earnings than Presbia PLC. Presbia PLC is trading at a lower price-to-earnings ratio than Hologic, indicating that it is currently the more affordable of the two stocks.


This table compares Presbia PLC and Hologic’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Presbia PLC N/A -150.69% -124.10%
Hologic 25.65% 23.18% 7.39%

Risk and Volatility

Presbia PLC has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Hologic has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.


Hologic beats Presbia PLC on 9 of the 13 factors compared between the two stocks.

About Presbia PLC

Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States. The Company’s lens, referred to as the microlens, is a miniature lens designed to be surgically implanted in a patient’s eye to improve that patient’s ability to see objects at close distances. The microlens is a disc shaped lens that has a refractive zone in the periphery designed to improve near vision problems associated with presbyopia and a central zone that is designed to improve distance vision. The Company’s solution is a standalone solution for plano presbyopes, or those individuals suffering from presbyopia but do not have any other visual disorders.

About Hologic

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

Receive News & Ratings for Presbia PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with's FREE daily email newsletter.